Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease - PubMed (original) (raw)
Review
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease
Martin A Wasserman et al. Am J Cardiol. 2003.
Abstract
This review addresses the role of oxidative stress in the pathology of atherosclerosis and why it is now believed that atherosclerosis is not only a disease of oxidative stress but also of chronic inflammation. Perhaps more importantly, this review also describes the vascular protectant (V-protectant) technology platform originated at AtheroGenics, Inc., from which a series of inhibitory compounds has emerged to treat a number of chronic inflammatory diseases, including atherosclerosis. In atherosclerosis, these drugs not only act as antioxidants, but also as lipid modulators, inhibitors of inflammation, and inhibitors of gene expression. It is also important to understand the basis for considering vascular cell adhesion molecule-1 (VCAM-1) as a reduction-oxidation-sensitive protein, which has a key role in the early phases of atherosclerosis. The review concludes with a description of the design and chemistry of AtheroGenics' lead clinical development compound, AGI-1067, and an analysis of its preclinical in vitro and in vivo profile. AGI-1067 is a novel, potent antioxidant with anti-inflammatory properties. It inhibits gene expression of VCAM-1 and monocyte chemoattractant protein-1, decreases low-density lipoprotein cholesterol levels, and prevents atherosclerosis in a number of animal models. AGI-1067 is currently undergoing clinical trials as an antiatherosclerotic agent.
Similar articles
- AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Serebruany VL, Malinin A, Eisert C, Ong S. Serebruany VL, et al. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):635-41. doi: 10.1586/14779072.5.4.635. Expert Rev Cardiovasc Ther. 2007. PMID: 17605642 Review. - AGI-1067: a novel vascular protectant for prevention of restenosis.
Franks AM, Gardner SF. Franks AM, et al. Ann Pharmacother. 2006 Jan;40(1):66-73. doi: 10.1345/aph.1G142. Epub 2005 Nov 22. Ann Pharmacother. 2006. PMID: 16303986 Review. - Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Tardif JC. Tardif JC. Am J Cardiol. 2003 Feb 6;91(3A):41A-49A. doi: 10.1016/s0002-9149(02)03149-1. Am J Cardiol. 2003. PMID: 12645643 Review. - Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
Kunsch C, Luchoomun J, Grey JY, Olliff LK, Saint LB, Arrendale RF, Wasserman MA, Saxena U, Medford RM. Kunsch C, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9. doi: 10.1124/jpet.103.059733. Epub 2003 Nov 14. J Pharmacol Exp Ther. 2004. PMID: 14617690 - AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Sundell CL, Somers PK, Meng CQ, Hoong LK, Suen KL, Hill RR, Landers LK, Chapman A, Butteiger D, Jones M, Edwards D, Daugherty A, Wasserman MA, Alexander RW, Medford RM, Saxena U. Sundell CL, et al. J Pharmacol Exp Ther. 2003 Jun;305(3):1116-23. doi: 10.1124/jpet.102.048132. Epub 2003 Mar 6. J Pharmacol Exp Ther. 2003. PMID: 12626663
Cited by
- PLGA Nanoparticles Containing VCAM-1 Inhibitor Succinobucol and Chemotherapeutic Doxorubicin as Therapy against Primary Tumors and Their Lung Metastases.
Wang J, Wang F, Xie D, Zhou M, Liao J, Wu H, Dai Y, Huang J, Zhao Y. Wang J, et al. Pharmaceutics. 2023 Jan 20;15(2):349. doi: 10.3390/pharmaceutics15020349. Pharmaceutics. 2023. PMID: 36839671 Free PMC article. - A bumpy and winding but right path to domestic drug-eluting coronary stents.
Cho JY, Ahn Y, Jeong MH. Cho JY, et al. Korean Circ J. 2013 Oct;43(10):645-54. doi: 10.4070/kcj.2013.43.10.645. Korean Circ J. 2013. PMID: 24255648 Free PMC article. Review. - Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Serebruany V, Malinin A, Qiu FH, Xu XC, Kunsch C, Scott R; ALPS Study Group. Serebruany V, et al. J Thromb Thrombolysis. 2009 May;27(4):438-46. doi: 10.1007/s11239-008-0233-y. Epub 2008 Jun 3. J Thromb Thrombolysis. 2009. PMID: 18521540 Clinical Trial. - Antioxidants: the good, the bad and the ugly.
Tardif JC. Tardif JC. Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):61B-65B. doi: 10.1016/s0828-282x(06)70988-6. Can J Cardiol. 2006. PMID: 16498514 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous